First-Line Cemiplimab + Chemotherapy Improves Quality of Life and Delays Disease Deterioration in Advanced NSCLC Without Driver Mutations

The results of the EMPOWER-Lung 3 study support the use of cemiplimab in combination with chemotherapy as a first-line treatment option for patients with advanced NSCLC without driver mutations.